Eversept Partners LP Sells 1,129,335 Shares of InflaRx (NASDAQ:IFRX)

Eversept Partners LP cut its stake in shares of InflaRx (NASDAQ:IFRX - Free Report) by 69.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 492,452 shares of the company's stock after selling 1,129,335 shares during the period. Eversept Partners LP owned 0.84% of InflaRx worth $1,216,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in IFRX. Walleye Capital LLC bought a new stake in shares of InflaRx in the fourth quarter valued at approximately $51,000. Raymond James Financial Inc. bought a new position in shares of InflaRx in the 4th quarter valued at $1,576,000. Geode Capital Management LLC raised its holdings in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after buying an additional 11,900 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock worth $275,000 after buying an additional 19,000 shares during the last quarter. Institutional investors own 42.39% of the company's stock.

Wall Street Analysts Forecast Growth

IFRX has been the subject of several research analyst reports. Guggenheim boosted their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a research note on Friday, March 21st.

InflaRx Stock Down 1.5 %

Shares of IFRX stock traded down $0.02 during mid-day trading on Friday, reaching $1.30. 86,652 shares of the stock traded hands, compared to its average volume of 225,782. The company has a market cap of $87.27 million, a price-to-earnings ratio of -1.20 and a beta of 2.21. The stock's fifty day simple moving average is $1.22 and its two-hundred day simple moving average is $1.82. InflaRx has a 1-year low of $0.82 and a 1-year high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. On average, equities research analysts anticipate that InflaRx will post -1.04 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.